Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,707 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Enrollment posture brief
Registry condition breast-cancer
OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 6 of 26
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
Deborah Farr, MD
NCT05245812
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
UNC Lineberger Comprehensive Cancer Center
NCT06727773
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
UNC Lineberger Comprehensive Cancer Center
NCT05472792
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
UNC Lineberger Comprehensive Cancer Center
NCT06902311
Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer
University of California, Los Angeles
NCT07208084
Cardiac Outcomes With Near-Complete Estrogen Deprivation
Duke University
NCT05309655
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
University of California, Davis
NCT06268665
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
BeOne Medicines
NCT07222267
A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation
Dartmouth-Hitchcock Medical Center
NCT06258993
A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania
Memorial Sloan Kettering Cancer Center
NCT05438511
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Biotheryx
NCT06515470
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Merck Sharp & Dohme
NCT06686394
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Washington University School of Medicine
NCT05837455
A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials
University of Pennsylvania
NCT07040891
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Hoffmann-La Roche
NCT07368998
Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction
Medical College of Wisconsin
NCT05223322
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex
NCT06440005
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
University of Texas Southwestern Medical Center
NCT03546686
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
UNC Lineberger Comprehensive Cancer Center
NCT07069595
Inspiratory Muscle Training in Obese Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT05193149
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Reshma L. Mahtani, D.O.
NCT06263543
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
University of Florida
NCT05074290
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
NCT06439693
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Criterium
NCT04567420
SAVE Trial: SAfe Opioid Use Video Education
University of Utah
NCT07044583
All-extremity Exercise During Breast Cancer Chemotherapy
University of Florida
NCT04914663
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
BicycleTx Limited
NCT06840483
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT04523857
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
Endomagnetics
NCT03796559
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Regor Pharmaceuticals
NCT05304962
VS-6766+Abema+Fulv in Met HR+/HER- BC
Adrienne G. Waks
NCT05608252
TRUDI: TDXD+Durva in HER2+/Low IBC
Filipa Lynce, MD
NCT05795101
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Dartmouth-Hitchcock Medical Center
NCT07071038
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Memorial Sloan Kettering Cancer Center
NCT07459673
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05412225
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
Oregon State University
NCT07055854
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
NCT04614194
Lifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management
West Virginia University
NCT06960720
A Novel Approach Utilizing Organ Specific Age Proteomics
UNC Lineberger Comprehensive Cancer Center
NCT06789653
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Cellectar Biosciences
NCT07311993
THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation
The University of Texas Medical Branch, Galveston
NCT06395506
Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance
University of California, San Diego
NCT07087691
A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer
University of Colorado, Denver
NCT06813053
A Study of Revaree Plus in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT07042581
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Sarah Sammons, MD
NCT06176261
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Novartis Pharmaceuticals
NCT06247995
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05570253
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Washington University School of Medicine
NCT04968964
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
Memorial Sloan Kettering Cancer Center
NCT05130801
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer page
1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 423 Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.